GoAI
Get started
GH Research PLC logo

GH Research PLC

GHRS

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$28.33

−$0.35 · -1.22%

Aug 21, 4:00 PM ET

Pre-market

$28.5522

+$0.2222 · +0.78%

Aug 24, 5:03 AM ET

GHRS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

40

Expensive

Momentum

63

Gaining

Sentiment

62

Bullish

Risk resilience

50

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.

Industry
Biotechnology
Sector
Healthcare
Headquarters
IE
CEO
Velichka Valcheva
Listed since
Jun 25, 2021
Employees
73

Market position

Day range

Current $28.33

52-week range

Current $28.33

Open
$28.83
Previous close
$28.68
Volume
141.75K
0.49× average
Average volume
292.22K
Average daily volume
Market cap
1.94B USD
Beta
1.29
Market reference 1
50-day average
$26.9829
+4.99% above average
200-day average
$19.1192
+48.18% above average

Financials

Financial statements

Income trends

Operating income

−60.68M USD-20.60%

Net income

−48.26M USD-23.86%
Income trends across reported periods−4.05M USD−24.64M USD−45.23M USD−65.82M USDOperating income, FY2021: −15.1M USDOperating income, FY2022: −30.55M USDOperating income, FY2023: −41.22M USDOperating income, FY2024: −50.31M USDOperating income, FY2025: −60.68M USDNet income, FY2021: −9.2M USDNet income, FY2022: −22.46M USDNet income, FY2023: −35.59M USDNet income, FY2024: −38.96M USDNet income, FY2025: −48.26M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −15.1M USD. Operating income FY2022 −30.55M USD. Operating income FY2023 −41.22M USD. Operating income FY2024 −50.31M USD. Operating income FY2025 −60.68M USD. Net income FY2021 −9.2M USD. Net income FY2022 −22.46M USD. Net income FY2023 −35.59M USD. Net income FY2024 −38.96M USD. Net income FY2025 −48.26M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold335K USD————
Gross profit−335K USD————
Research and development38.73M USD35.02M USD29.82M USD20.48M USD8.55M USD
Selling, general, and administrative21.61M USD15M USD11.12M USD10.06M USD6.54M USD
Operating expenses60.34M USD50.31M USD41.22M USD30.55M USD15.1M USD
Interest income2.63M USD2.63M USD1.89M USD858K USD9 USD
Interest expense463K USD717K USD723K USD—9K USD
Depreciation and amortization335K USD315K USD315K USD47K USD19K USD
Operating income−60.68M USD−50.31M USD−41.22M USD−30.55M USD−15.1M USD
Net income−48.26M USD−38.96M USD−35.59M USD−22.46M USD−9.2M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 2 misses, 1 met estimate
Average EPS surprise
+18.19%
11 comparable reports
Latest EPS result
-0.23
Estimate -0.29 · Beat by 19.58%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.13-0.3-0.48-0.65Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MetQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual -0.17, estimate -0.23, surprise +26.09%, Beat. Q2 2025, reported May 8, 2025: actual -0.19, estimate -0.61, surprise +68.85%, Beat. Q3 2025, reported Aug 7, 2025: actual -0.15, estimate -0.22, surprise +31.82%, Beat. Q4 2025, reported Nov 6, 2025: actual -0.23, estimate -0.23, surprise 0.00%, Met estimate. Q1 2026, reported Mar 5, 2026: actual -0.23, estimate -0.29, surprise +20.69%, Beat. Q2 2026, reported May 14, 2026: actual -0.31, estimate -0.27, surprise -14.81%, Miss. Q3 2026, reported Aug 6, 2026: actual -0.23, estimate -0.286, surprise +19.58%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.27, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

9 ratings
Strong buy00%
Buy9100%
Hold00%
Sell00%
Strong sell00%

GHRS news

globenewswire.com

GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update

Alignment with FDA on CMC and device plans for Phase 3 Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials Further strengthening of US and EU mebufotenin patent estate Phase 2a results in postpartum…

Read source
benzinga.com

Why Is GH Research Stock Trading Higher on Thursday?

GH Research PLC (NASDAQ:GHRS) and Definium Therapeutics Inc. (NASDAQ:DFTX) stocks are trading higher in response to Eli Lilly and Co. (NYSE:LLY) agreeing to acquire AtaiBeckley Inc. (NASDAQ:ATAI) in a deal valued at up…

Read source
proactiveinvestors.com

CleanSpark shares surge after company secures $6.6B data center lease agreement

CleanSpark Inc (NASDAQ:CLSK) shares surged more than 12% after the company announced a 20-year lease agreement for its Sandersville, Georgia data center...

Read source
proactiveinvestors.com

Tower Semiconductor shares jump as company announces Japan expansion to boost silicon photonics capacity

Tower Semiconductor (NASDAQ:TSEM) shares rose 13% on Tuesday after the company announced a strategic expansion of its silicon photonics, silicon germanium...

Read source
proactiveinvestors.com

Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says

The US Food and Drug Administration's finalized guidance on psychedelic drug development signals the agency remains receptive to helping developers navigate the approval process, a development that Jefferies said could…

Read source
globenewswire.com

GH Research Announces Publication of Phase 2a Postpartum Depression Results

DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance of two oral…

Read source

GHRS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding GHRS

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
10.44M
Weight
0.10%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
AdvisorShares Psychedelics ETF logoAdvisorShares Psychedelics ETFPSIL
Market value
2.55M
Weight
4.42%
AUM
57.72M USD
Expense ratio
1.84%
Price / 1D
$25.86-0.35%
iShares MSCI Ireland ETF logoiShares MSCI Ireland ETFEIRL
Market value
1.58M
Weight
2.00%
AUM
79.62M USD
Expense ratio
0.50%
Price / 1D
$83.9281+1.27%
Virtus Biotech Clinical Trials ETF logoVirtus Biotech Clinical Trials ETFBBC
Market value
422.05K
Weight
0.83%
AUM
51.06M USD
Expense ratio
0.65%
Price / 1D
$54.415+1.01%
State Street SPDR S&P International Small Cap ETF logoState Street SPDR S&P International Small Cap ETFGWX
Market value
323.39K
Weight
0.03%
AUM
927.26M USD
Expense ratio
0.40%
Price / 1D
$46.205+0.40%
Invesco Nasdaq Biotechnology ETF logoInvesco Nasdaq Biotechnology ETFIBBQ
Market value
115.84K
Weight
0.13%
AUM
94.57M USD
Expense ratio
0.19%
Price / 1D
$36.29+1.37%
ProShares Ultra Nasdaq Biotechnology logoProShares Ultra Nasdaq BiotechnologyBIB
Market value
66.21K
Weight
0.06%
AUM
103.78M USD
Expense ratio
1.19%
Price / 1D
$122.16+2.73%
First Trust IPOX Europe Equity Opportunities ETF logoFirst Trust IPOX Europe Equity Opportunities ETFFPXE
Market value
16.49K
Weight
0.33%
AUM
5.08M USD
Expense ratio
0.70%
Price / 1D
$33.9569+0.40%

Continue in GoAI

Research GHRS

research.disclaimer